Skip to main content
SpringerLink
Log in

Antiplatelet Therapy in the Prevention of Stroke

  • Section 2
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Aspirin (acetylsalicylic acid) is effective in reducing vascular outcome events in patients with atherosclerosis: a relative risk reduction of about 30% for stroke, 22% for stroke and death, and 15% for vascular mortality. It is probable that low and high dose aspirin are similar in efficacy. Complications are more frequent with high dose aspirin than with low doses.

Four randomised trials evaluating sulfinpyrazone vs placebo, and 3 trials evaluating sulfinpyrazone vs aspirin, showed more cerebrovascular events in the sulfinpyrazone group than in the aspirin and placebo groups.

One small trial comparing dipyridamole with placebo in patients with cerebrovascular disease found no difference between the 2 groups in outcome. No other studies have compared dipyridamole alone with placebo or aspirin. The European Stroke Prevention Study II is currently in progress and is comparing dipyridamole + aspirin, dipyridamole, aspirin, and placebo.

In the first year, the Ticlopidine Aspirin Stroke Study (TASS) showed a 42% risk reduction for stroke and death using the efficacy analysis and a 47% risk reduction for stroke and stroke death. Ticlopidine was more effective than aspirin in reducing stroke in both males and females. Apart from a reversible severe neutropenia in 0.86% of patients, ticlopidine-related adverse effects were relatively benign and reversible. The Canadian-American Ticlopidine Study (CATS) compared ticlopidine with placebo in patients with completed major strokes. The cumulative event rates for the primary outcome events of stroke, myocardial infarction and vascular death, using the efficacy approach, show clear evidence of separation almost immediately after randomisation, consistent with a constant risk reduction of about 30% in the ticlopidine group. These data provide strong evidence that ticlopidine conveys a clinically important reduction in the risk of thromboembolic events in patients with a history of completed thromboembolic stroke.

In conclusion, aspirin is effective in preventing atherothrombotic morbidity and mortality. It reduces the overall vascular event rate by about 25%. Sulfinpyrazone and dipyridamole appear to add nothing important over aspirin alone. Ticlopidine is more effective than aspirin in preventing stroke. The modest, reversible risk of neutropenia, affecting less than 1% of patients, makes the benefit: risk ratio a reasonable one.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyridamole in cerebral vascular disease. British Medical Journal 1: 614–615, 1969

    Article  PubMed  CAS  Google Scholar 

  • American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results. Stroke 16: 406–415, 1985

    Article  Google Scholar 

  • Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. British Medical Journal 296: 320–331, 1988

    Article  Google Scholar 

  • Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, et al. Studia della Ticlopidina nell’Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 82: 17–26, 1990

    Article  PubMed  CAS  Google Scholar 

  • Barnett HJM. Proceedings of the International Conference on Stroke, Geneva, Switzerland, May 30–June 1, 1991. The World Federation of Neurology, 1991

  • Blakely JA. A prospective trial of sulfinpyrazone and survival after thrombotic stroke. Thrombosis et Diathesis Haemorrhagica 42: 161, 1979

    Google Scholar 

  • Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New England Journal of Medicine 323: 1505–1511, 1990

    Article  Google Scholar 

  • Bousser MG, Eschwege E, Haguenau M, et al. ‘AICLA’ controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 14: 5–14, 1983

    Article  PubMed  CAS  Google Scholar 

  • Byer JA, Easton JD. Therapy of ischemic cerebrovascular disease. Annals of Internal Medicine 93: 742–756, 1980

    PubMed  CAS  Google Scholar 

  • Canadian Cooperative Study Group: a randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine 299: 53–59, 1978

    Article  Google Scholar 

  • Chesebro JH, Fuster V, Pumphrey CW, et al. Combined warfarin-platelet inhibitor antithrombotic therapy in prosthetic heart valve replacement. Circulation 64(Suppl. IV): IV76, 1981

    Google Scholar 

  • Connolly SJ, et al. Results of the Canadian Atrial Fibrillation Study. Journal of the American College of Cardiology, in press, 1991

    Google Scholar 

  • Dutch TIA Trial Study Group. The Dutch TIA Trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke 19: 512–517, 1988

    Article  Google Scholar 

  • Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs. 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine 325: 1261–1266, 1991

    Article  Google Scholar 

  • Easton JD, Hart RG, Kaste M, Sherman DG. Diagnosis and management of ischemic stroke. Part I. Threatened stroke and its management. Current Problems in Cardiology 8: 1–76, 1983

    Article  CAS  Google Scholar 

  • ESPS Group: the European stroke prevention study (ESPS). Principal end-points. Lancet 2: 1351–1354, 1987

    Google Scholar 

  • European Carotid Surgery Trialists’ Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet 337: 1235–1243, 1991

    Article  Google Scholar 

  • Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 8: 301–316, 1977

    Article  PubMed  CAS  Google Scholar 

  • Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia, part II. Stroke 9: 309–319, 1978

    Article  PubMed  CAS  Google Scholar 

  • Gent M, Barnett HJ, Sackett DL, Taylor DW. A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodologic issues. Circulation 62(Suppl. V): V97–V105, 1980

    PubMed  CAS  Google Scholar 

  • Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke: design, organization and baseline results. Stroke 19: 1203–1210, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gent M, Easton JD, Hachinski VC, Panak E, Sicurella J, et al. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1: 1215–1220, 1989

    Article  PubMed  CAS  Google Scholar 

  • Guiraud-Chaumeil B, Rascol A, David A, Boneu B, Clanet M, et al. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-aggregants plaquettaires; resultats d’un essai therapeutique controle de 3 ans. Revue Neurologique 138: 367–385, 1982

    PubMed  CAS  Google Scholar 

  • Hass WK, Easton JD, Adams Jr HP, Pryse-Phillips W, Molony BA, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine 321: 501–507, 1989

    Article  PubMed  CAS  Google Scholar 

  • Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effect of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. Journal of Internal Medicine 227: 301–308, 1990

    Article  PubMed  CAS  Google Scholar 

  • Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1: 175–179, 1989

    Article  PubMed  CAS  Google Scholar 

  • Peto R, Gray R, Collins R, Wheatley K, Hennekens C, et al. Randomized trial of prophylactic daily aspirin in British male doctors. British Medical Journal 1: 313–316, 1988

    Article  Google Scholar 

  • Robertson JT, Dugdale M, Salky N, Robinson H. The effect of a platelet inhibiting drug in the therapy of patients with transient ischaemic attacks and strokes. Thrombosis et Diathesis Haemorrhagica 34: 598, 1975

    PubMed  CAS  Google Scholar 

  • Salt Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 2: 1345–1349, 1991

    Article  Google Scholar 

  • Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. New England Journal of Medicine 323: 147–152, 1990

    Article  PubMed  CAS  Google Scholar 

  • Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. New England Journal of Medicine 321: 129–135, 1989

    Article  Google Scholar 

  • Stroke Prevention in Atrial Fibrillation Study Group. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. New England Journal of Medicine 322: 863–868, 1990

    Google Scholar 

  • Swedish Cooperative Study. High-dose acetylsalicylic acid after cerebral infarction. Stroke 18: 325–334, 1987

    Article  Google Scholar 

  • Tohgi H. The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study. Agents and Actions 15 (Suppl.): 279–282, 1984

    Article  PubMed  CAS  Google Scholar 

  • UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. British Medical Journal 1: 316–320, 1988

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Rhode Island Hospital-Brown University, 110 Lockwood Street, Providence, Rhode Island, 02903-4801, USA

    J. D. Easton (Professor and Chairman)

Authors
  1. J. D. Easton
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

A substantial portion of this text was published in Cerebrovascular Diseases as part of the Symposium on Aspects of Stroke Prevention held in conjunction with the International Conference on Stroke, Geneva, Switzerland, May 30 to June 1, 1991.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Easton, J.D. Antiplatelet Therapy in the Prevention of Stroke. Drugs 42 (Suppl 5), 39–50 (1991). https://doi.org/10.2165/00003495-199100425-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199100425-00007

Keywords

Search

Navigation